Helge Karch

Dr. Helge Karch


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAlexander W. Friedrich
Alexander W. Friedrich
MBMartina Bielaszewska
Martina Bielaszewska
WZWen‐Lan Zhang
Wen‐Lan Zhang
MPMatthias Pulz
Matthias Pulz
TKThorsten Kuczius
Thorsten Kuczius
HKHelge Karch
Helge Karch
Shiga toxin (Stx)–producing Escherichia coli (STEC) from patients with hemolytic-uremic syndrome (HUS), patients with diarrhea without HUS, or asympt

1 October 2005 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
HKHelge Karch
Helge Karch
PTPhillip I. Tarr
Phillip I. Tarr
MBMartina Bielaszewska
Martina Bielaszewska

1 June 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MBMartina Bielaszewska
Martina Bielaszewska
EIEvgeny A. Idelevich
Evgeny A. Idelevich
WZWenlan Zhang
Wenlan Zhang
ABAndreas Bauwens
Andreas Bauwens
FSFrieder Schaumburg
Frieder Schaumburg
HKHelge Karch
Helge Karch
The role of antibiotics in treatment of enterohemorrhagic Escherichia coli (EHEC) infections is controversial because of concerns about triggering hemolytic-uremic syndrome (HUS) by increasing Shiga toxin (Stx) production. During the recent large EHEC O104:H4 outbreak, antibiotic therapy was indicated for some patients. We tested a diverse panel of antibiotics to which the outbreak strain is susceptible to interrogate the effects of subinhibitory antibiotic concentrations on induction of stx 2 -harboring bacteriophages, stx 2 transcription, and Stx2 production in this emerging pathogen. Ciprofloxacin significantly increased stx 2 -harboring phage induction and Stx2 production in outbreak isolates ( P values of <0.001 to 0.1) and chloramphenicol, meropenem, azithromycin, rifaximin, and tigecycline significantly decreased them ( P ≤ 0.05). Ciprofloxacin and chloramphenicol significantly upregulated and downregulated stx 2 transcription, respectively ( P < 0.01); the other antibiotics had insignificant effects ( P > 0.1). Meropenem, azithromycin, and rifaximin, which were used for necessary therapeutic or prophylactic interventions during the EHEC O104:H4 outbreak, as well as tigecycline, neither induced stx 2 -harboring phages nor increased stx 2 transcription or Stx2 production in the outbreak strain. These antibiotics might represent therapeutic options for patients with EHEC O104:H4 infection if antibiotic treatment is inevitable. We await further analysis of the epidemic to determine if usage of these agents was associated with an altered risk of developing HUS.

1 June 2001 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
HKHelge Karch
Helge Karch
MBMartina Bielaszewska
Martina Bielaszewska

1 April 2002 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
WZWenlan Zhang
Wenlan Zhang
MBMartina Bielaszewska
Martina Bielaszewska
TKThorsten Kuczius
Thorsten Kuczius
HKHelge Karch
Helge Karch
By using sequence analysis of Shiga toxin 1 (Stx 1) genes from human and ovine Stx-producing Escherichia coli (STEC) strains, we identified an Stx1 variant in STEC of human origin that was identical to the Stx1 variant from ovine STEC, but demonstrated only 97.1 and 96.6% amino acid sequence identity in its A and B subunits, respectively, to the Stx1 encoded by bacteriophage 933J. We designated this variant “Stx1c” and developed stxB 1 restriction fragment length polymorphism and stx 1c -specific PCR strategies to determine the frequency and distribution of stx 1c among 212 STEC strains isolated from humans. stx 1c was identified in 36 (17.0%) of 212 STEC strains, 19 of which originated from asymptomatic subjects and 16 of which were from patients with uncomplicated diarrhea. stx 1c was most frequently (in 23 STEC strains [63.9%]) associated with stx 2d , but 12 (33.3%) of the 36 STEC strains possessed stx 1c only. A single STEC strain possessed stx 1c together with stx 2 and was isolated from a patient with hemolytic-uremic syndrome. All 36 stx 1c -positive STEC strains were eae negative and belonged to 10 different serogroups, none of which was O157, O26, O103, O111, or O145. Stx1c was produced by all stx 1c -containing STEC strains, but reacted weakly with a commercial immunoassay. We conclude that STEC strains harboring the stx 1c variant account for a significant proportion of human STEC isolates. The procedures developed in this study now allow the determination of the frequency of STEC strains harboring stx 1c among clinical STEC isolates and their association with human disease in prospective studies.

1 June 2003 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
AJAndreas Janka
Andreas Janka
MBMartina Bielaszewska
Martina Bielaszewska
UDUlrich Dobrindt
Ulrich Dobrindt
LGLilo Greune
Lilo Greune
MSM. Alexander Schmidt
M. Alexander Schmidt
HKHelge Karch
Helge Karch
We identified a cytolethal distending toxin ( cdt ) gene cluster in 87, 6, and 0% of sorbitol-fermenting (SF) enterohemorrhagic Escherichia coli (EHEC) O157:H − , EHEC O157:H7, and E . coli O55:H7/H − strains, respectively. The toxin was expressed by the wild-type EHEC O157 strains and by a cdt -containing cosmid from a library of SF EHEC O157:H − strain 493/89. The cdt flanks in strain 493/89 were homologous to bacteriophages P2 and lambda. Our data demonstrate that cdt , encoding a potential virulence factor, is present in the EHEC O157 complex and suggest that cdt may have been acquired by phage transduction.